Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics

• Published in: Thrombosis research 2016-01, Vol.137, p.178-183
• Main Authors: Testa, Sophie, Tripodi, Armando, Legnani, Cristina, Pengo, Vittorio, Abbate, Rosanna, Dellanoce, Claudia, Carraro, Paolo, Salomone, Luisa, Paniccia, Rita, Paoletti, Oriana, Poli, Daniela, Palareti, Gualtiero
• Format: Article
• Language: English
• Subjects: Administration, Oral; Aged; Anti-FXa; Anticoagulants - pharmacokinetics; Anticoagulants - therapeutic use; Atrial Fibrillation - blood; Atrial Fibrillation - drug therapy; Atrial Fibrillation - epidemiology; Biological Availability; Comorbidity; Creatinine clearance; Dilute thrombin time; DOAC; Female; Glomerular Filtration Rate - drug effects; Hematology, Oncology and Palliative Medicine; Humans; Inter-individual variability; Intra-individual variability; Italy - epidemiology; Male; Prevalence; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Thromboembolism - blood; Thromboembolism - epidemiology; Thromboembolism - prevention & control; Treatment Outcome
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2015.12.001

Abstract Introduction Direct oral anticoagulant (DOAC) intra- and inter-individual variability was previously reported, but its magnitude is still considered negligible for patient management. Objective To evaluate inter- and intra-individual variability in real-world atrial fibrillation patients on dabigatran, rivaroxaban or apixaban in four Italian anticoagulation clinics and to assess the correlation between DOAC plasma concentration and creatinine-clearance (CrCl). Materials and Methods A total of 330 consecutive patients were enrolled, of which 160 were on dabigatran (70 and 90 taking 150 mg or 110 mg twice-daily, respectively), 71 on rivaroxaban (37 and 34 taking 20 mg or 15 mg once-daily) and 99 on apixaban (73 and 26 taking 5 mg or 2.5 mg twice-daily). Blood was taken at trough and peak within the first month (15–25 days) of treatment. Diluted-thrombin-time (dTT) calibrated for dabigatran and anti-FXa calibrated for rivaroxaban or apixaban was performed. Results Mean inter-individual variability expressed as overall CV values for all drugs was lower at peak (CV = 46%) than at trough (CV = 63%). Mean CV% intra-individual variability was 36.6% at trough and 34.0% at peak. Correlation with CrCl was poor for all drugs and only dabigatran at trough showed a significant correlation. Conclusion This multicenter study confirms high DOAC inter-individual variability that cannot be explained by the rate of renal clearance to which the three DOAC were subjected since the correlation with CrCl was relatively poor. This poor correlation suggests caution in using CrCl as the sole laboratory parameter to indirectly evaluate residual circulating DOAC.